Table 2 Results of univariate analysis of PD-L1, PD-1, CD8, CD4 and CD3 in relation to durable clinical benefit are shown for the derivation cohort.

From: Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

Variables	Derivation cohort
Variables	DCB rates (%)	Univariate OR (95% CI)	p value	Multivariate OR (95% CI)	p value
Tumour PD-L1 expression			0.014		0.041
<1% (n = 50)	18	1.0		1.00
1–49% (n = 8)	0	0		0.00
≥50% (n = 8)	75	13.6 (2.3–79.0)		11.8 (1.7–79.7)
Stromal infiltration of PD-L1⁺ IC			0.36
Low infiltration (n = 40)	18	1.0
Intermediate infiltration (n = 15)	33	2.4 (0.61–9.1)
High infiltration (n = 9)	33	2.4 (0.47–11.8)
Stromal infiltration of PD-1⁺ IC			0.047
Low infiltration (n = 38)	13	1.0
Intermediate infiltration (n = 21)	29	2.6 (0.70–10.0)
High infiltration (n = 7)	57	8.8 (1.5–51.6)
Tumour infiltration of CD8⁺ IC			0.11
Low infiltration (n = 35)	14	1.0
Intermediate infiltration (n = 18)	22	1.7 (0.40–7.4)
High infiltration (n = 14)	43	4.5 (1.1–18.6)
Stromal infiltration of CD8⁺ IC			0.063
Low infiltration (n = 15)	7	1.0
Intermediate infiltration (n = 21)	14	2.3 (0.22–24.9)
High infiltration (n = 30)	37	8.1 (0.93–70.3)
Stromal infiltration of CD3⁺ IC			0.046
Low infiltration (n = 22)	5	1.0
Intermediate infiltration (n = 21)	24	6.6 (0.7–61.9)
High infiltration (n = 22)	41	14.5 (1.7–128.4)
Stromal infiltration of CD4⁺ IC			0.044
Low infiltration (n = 16)	6	1.0
Intermediate infiltration (n = 13)	8	1.3 (0.071–22.1)
High infiltration (n = 36)	36	8.5 (1.0–71.7)
Combined tumour and stromal infiltration of CD8⁺ IC			0.030		0.073
Low infiltration of tumour and stromal CD8⁺ IC (n = 28)	14	1.0		1.0
High infiltration of tumour or stromal CD8⁺ IC (n = 14)	7	0.46 (0.047–4.6)		0.32 (0.028–3.8)
High infiltration of tumour and stromal CD8⁺ IC (n = 24)	42	4.3 (1.1–16.3)		3.5 (0.78–15.9)
Combined stromal infiltration of PD-1⁺ and CD8⁺ IC			0.027
Low infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 28)	11	1.0
High infiltration of stromal PD-1⁺ or CD8⁺ IC (n = 17)	18	1.8 (0.32–10.1)
High infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 20)	45	6.8 (1.5–30.2)
Combined stromal infiltration of PD-L1⁺ and CD8⁺ IC			0.024
Low infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 30)	7	1.0
High infiltration of stromal PD-L1⁺ or CD8⁺ IC (n = 16)	44	10.9 (1.9–62.1)
High infiltration of PD-L1⁺ and CD8⁺ IC (n = 18)	33	7.0 (1.2–39.8)

Statistically significant p < 0.05 values are in bold

Back to article page

Table 2 Results of univariate analysis of PD-L1, PD-1, CD8, CD4 and CD3 in relation to durable clinical benefit are shown for the derivation cohort.

Search

Quick links